Alex Sapir - 03 Jul 2024 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
President & Chief Executive Officer, Director
Signature
/s/ Greg Tourangeau as attorney-in-fact for Alex Sapir
Issuer symbol
FULC
Transactions as of
03 Jul 2024
Net transactions value
+$490,500
Form type
4
Filing time
08 Jul 2024, 08:00:03 UTC
Previous filing
05 Mar 2024
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FULC Common Stock Options Exercise $490,500 +150,000 +346% $3.27* 193,360 03 Jul 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock option - Right to Buy Options Exercise $0 -150,000 -6.2% $0.000000 2,280,400 03 Jul 2024 Common Stock 150,000 $3.27 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
F2 This option was granted on May 12, 2023 and vested 25% on the first anniversary of the vesting commencement date of May 12, 2023. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

Remarks:

President & Chief Executive Officer